Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda

Reuters

09/04

Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda

GAITHERSBURG, Md., Sept. 4, 2025 - Novavax, Inc. (Nasdaq: NVAX) has announced the regulatory approval of its COVID-19 vaccine, Nuvaxovid®, in Japan. The approval applies to its use as an initial immunization for individuals aged six years and older, and as a booster for those aged 12 and older. This milestone triggers a payment from Takeda to Novavax, under their collaboration agreement. The vaccine targets the SARS-CoV-2 Omicron LP.8.1 variant and offers a protein-based, non-mRNA option in the Japanese market. Novavax is also set to receive royalties on net sales from Takeda. Specific payment amounts remain confidential due to contractual agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH64907) on September 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564371273"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564371273\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564371273?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564371273","market":"fut","top_or_hot":-1,"title":"Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GAITHERSBURG, Md., Sept. 4, 2025 - Novavax, Inc. (Nasdaq: NVAX) has announced the regulatory approval of its COVID-19 vaccine, Nuvaxovid®, in Japan. The approval applies to its use as an initial immunization for individuals aged six years and older, and as a booster for those aged 12 and older. This milestone triggers a payment from Takeda to Novavax, under their collaboration agreement. The vaccine targets the SARS-CoV-2 Omicron LP.8.1 variant and offers a protein-based, non-mRNA option in the Japanese market. Novavax is also set to receive royalties on net sales from Takeda. Specific payment amounts remain confidential due to contractual agreements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH64907) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-04 20:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GAITHERSBURG, Md., Sept. 4, 2025 - Novavax, Inc. (Nasdaq: NVAX) has announced the regulatory approval of its COVID-19 vaccine, Nuvaxovid®, in Japan. The approval applies to its use as an initial immunization for individuals aged six years and older, and as a booster for those aged 12 and older. This milestone triggers a payment from Takeda to Novavax, under their collaboration agreement. The vaccine targets the SARS-CoV-2 Omicron LP.8.1 variant and offers a protein-based, non-mRNA option in the Japanese market. Novavax is also set to receive royalties on net sales from Takeda. Specific payment amounts remain confidential due to contractual agreements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH64907) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美國抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL7KhvNT:1","article_id":"2564371273","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564371273","pubTimestamp":1756987380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GAITHERSBURG, Md., Sept. 4, 2025 - Novavax, Inc.  has announced the regulatory approval of its COVID-19 vaccine, Nuvaxovid, in Japan. The approval applies to its use as an initial immunization for individuals aged six years and older, and as a booster for those aged 12 and older. This milestone triggers a payment from Takeda to Novavax, under their collaboration agreement. The vaccine targets the SARS-CoV-2 Omicron LP.8.1 variant and offers a protein-based, non-mRNA option in the Japanese market. Novavax is also set to receive royalties on net sales from Takeda. Specific payment amounts remain confidential due to contractual agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to g","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4547":"WSB热门概念","BK4139":"生物科技","NVAX":"诺瓦瓦克斯医药"},"translate_title":"Novavax的Nuvaxovid®COVID-19疫苗在日本获得监管批准，触发武田的里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"Novavax's Nuvaxovid® COVID-19 Vaccine Receives Regulatory Approval in Japan, Triggering Milestone Payment from Takeda\n    \n\n        GAITHERSBURG, Md., Sept. 4, 2025 - Novavax, Inc. (Nasdaq: NVAX) has announced the regulatory approval of its COVID-19 vaccine, Nuvaxovid®, in Japan. The approval applies to its use as an initial immunization for individuals aged six years and older, and as a booster for those aged 12 and older. This milestone triggers a payment from Takeda to Novavax, under their collaboration agreement. The vaccine targets the SARS-CoV-2 Omicron LP.8.1 variant and offers a protein-based, non-mRNA option in the Japanese market. Novavax is also set to receive royalties on net sales from Takeda. Specific payment amounts remain confidential due to contractual agreements.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novavax Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH64907) on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}